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Abstract 
Background: The changes in metabolic pathways and metabolites due to critical illness result in a highly complex 
and dynamic metabolic state, making safe, effective management of hyperglycemia and hypoglycemia difficult. In 
addition, clinical practices can vary significantly, thus making GC protocols difficult to generalize across units.The 
aim of this study was to provide a retrospective analysis of the safety, performance and workload of the stochastic 
targeted (STAR) glycemic control (GC) protocol to demonstrate that patient-specific, safe, effective GC is possible with 
the STAR protocol and that it is also generalizable across/over different units and clinical practices.
Methods: Retrospective analysis of STAR GC in the Christchurch Hospital Intensive Care Unit (ICU), New Zealand 
(267 patients), and the Gyula Hospital, Hungary (47 patients), is analyzed (2011–2015). STAR Christchurch (BG target 
4.4–8.0 mmol/L) is also compared to the Specialized Relative Insulin and Nutrition Tables (SPRINT) protocol (BG target 
4.4–6.1 mmol/L) implemented in the Christchurch Hospital ICU, New Zealand (292 patients, 2005–2007). Cohort 
mortality, effectiveness and safety of glycemic control and nutrition delivered are compared using nonparametric 
statistics.
Results: Both STAR implementations and SPRINT resulted in over 86 % of time per episode in the blood glucose (BG) 
band of 4.4–8.0 mmol/L. Patients treated using STAR in Christchurch ICU spent 36.7 % less time on protocol and were 
fed significantly more than those treated with SPRINT (73 vs. 86 % of caloric target). The results from STAR in both 
Christchurch and Gyula were very similar, with the BG distributions being almost identical. STAR provided safe GC with 
very few patients experiencing severe hypoglycemia (BG < 2.2 mmol/L, <5 patients, 1.5 %).
Conclusions: STAR outperformed its predecessor, SPRINT, by providing higher nutrition and equally safe, effective 
control for all the days of patient stay, while lowering the number of measurements and interventions required. The 
STAR protocol has the ability to deliver high performance and high safety across patient types, time, clinical practice 
culture (Christchurch and Gyula) and clinical resources.
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Background
Stress-induced insulin resistance, resulting in hypergly-
cemia, is often experienced by intensive care unit (ICU) 
patients [1–3] and is associated with increased morbid-
ity and mortality [1, 2, 4]. Glycemic variability in these 
highly dynamic patients has also been independently 
related to increased mortality [5, 6]. Studies have shown 
that safe, effective glycemic control (GC) that modulates 
exogenous insulin and/or nutrition significantly reduces 
the number of negative effects of dysglycemia [7–9], 
including reductions in the rate and severity of organ fail-
ure [10] and cost of care [11, 12].
The stress response a critically ill patient experiences 
is highly complex, variable and dynamic [13], making 
safe, effective control of blood glucose (BG) difficult. 
This is one reason a number of studies may have failed to 
achieve consistent, safe and effective GC [14–20]. These 
negative and inconclusive outcomes could be largely due 
to the studies having a significant increase in the risk of 
hypoglycemia (17–29  % <2.2  mmol/L), which is associ-
ated with increased mortality [21–23], and can be asso-
ciated with large changes in patient response to insulin 
over short periods [13, 24, 25], particularly in the first 
48  h [26], where many hypoglycemic events occur and 
there is a strong association with mortality [22].
It is thus possible that previous studies failed to achieve 
safe consistent GC due to the GC protocols not being 
able to observe or identify individual patient-specific 
dynamics, but providing GC based on an absolute BG 
value. A more patient-specific approach to GC is needed 
to successfully manage such significant inter- and intra-
patient variability [24, 27]. The ability to provide safe, 
effective control across patients and clinical practice is 
a necessary requirement before being able to assess the 
impact of GC on clinical outcomes.
The tablet-computer-based stochastic targeted (STAR) 
GC protocol provides patient-specific GC [28, 29]. STAR 
uses a clinically validated pharmacokinetic and phar-
macodynamic model of the insulin–glucose system [30, 
31] and a cohort-based model of insulin sensitivity vari-
ability [32, 33] to compute optimal patient-specific insu-
lin and nutrition interventions that maximize control 
and nutrition, while maintaining a maximum 5 % risk of 
BG < 4.4 mmol/L [28, 29]. STAR also allows variable 1- 
to 3-hourly BG measurement frequency to help manage 
nursing workload. STAR has been the standard of care in 
Christchurch Hospital ICU, Christchurch, New Zealand, 
and in the Kálmán Pándy Hospital ICU, Gyula, Hungary, 
since 2011. The predecessor of STAR in Christchurch 
was the Specialized Relative Insulin and Nutrition Tables 
(SPRINT) [8, 10].
The aim of this dual-center retrospective analysis is to 
demonstrate that patient-specific, safe, effective GC is 
possible with the STAR protocol and that it is also gener-
alizable across/over different units and clinical practices.
Methods
Comparisons
This dual-center retrospective analysis makes two com-
parisons to assess.
1. Performance and safety: STAR is compared to 
SPRINT in Christchurch to provide a comparison 
between patient protocols in the same unit, and dem-
onstrate equivalent or better performance and safety 
of STAR to a successful protocol [8].
2. Generalizability: STAR Christchurch is compared to 
STAR Gyula to test generalizability of safety and per-
formance over significantly different clinical practice 
cultures and approaches.
The metrics compared are:
  • Performance: Percentage of time in BG band (4.4–
8.0 mmol/L) [34].
  • Safety: Number of severe hypoglycemic cases 
(BG < 2.2 mmol/L) [21].




This study compares clinical data from three cohorts:
1. Patients treated using STAR in Christchurch Hospi-
tal ICU, Christchurch, New Zealand, from June 2011 
to May 2015.
2. Patients treated using STAR in Kálmán Pándy Hos-
pital ICU, Gyula, Hungary, from December 2011 to 
May 2015.
3. Patients treated using SPRINT in Christchurch Hospi-
tal ICU, Christchurch, NZ, from July 2005 to May 2007.
The following patients in these three cohorts were 
excluded: those who spent less than 10 h on protocol and 
were fed on average greater than 120 % of their SCCM/
ACCP caloric target [35]. Patients who spent less than 
10 h on protocol were excluded as they were considered 
to not have a significant amount of time on protocol to 
fairly assess the performance or be clinically affected by 
good GC. Patients who were fed greater than 120  % of 
their calorific target were excluded as this is well outside 
the recommendations of STAR and SPRINT, as well as 
well-accepted clinical guidelines. The number of patient 
episodes excluded due to each of these filtering criteria is 
given in Table 1.
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Patients on the STAR protocol who did not target the 
4.4–8.0  mmol/L BG band were also excluded. Thus, all 
STAR patients compared used the STAR framework in 
the same manner with respect to BG and nutrition tar-
gets. It should be noted that all SPRINT patients targeted 
the 4.0–6.1  mmol/L BG band as the SPRINT protocol 
was not flexible to different targets.
Demographic data for these cohorts are presented in 
Tables 2 and 3, aligned with the two main comparisons. 
Some data are unavailable for the STAR Gyula cohort in 
Table  3 due to differences in the typical data collected. 
The missing data do not impact the assessment of gener-
alizability of the safety and performance of STAR.
Ethics, consent and permissions
The Upper South Regional Ethics Committee, New Zea-
land, granted approval for the retrospective audit, anal-
ysis and publication of the Christchurch patient data. 
According to the local ethical codes in Hungary, the 
study of the Gyula cohort was considered a clinical data 
audit and only required depersonalization of data with-
out the need for individual patient consent to analyze or 
publish the anonymized data.
Clinical practice and implementation: Christchurch Hospital 
ICU, New Zealand
STAR has been the standard of care in the Christchurch 
Hospital ICU since June 2011. This facility is a mixed 
medical, tertiary affiliated ICU. Starting criteria for STAR 
in Christchurch is two successive BG measurements over 
8 mmol/L within a 4-h period. IV insulin is delivered in 
hourly bolus form, with added background infusions of 
up to 3U/h when insulin requirements are high and sus-
tained [28, 29]. Blood for BG measurement was typically 
taken directly from an arterial line and measured using 
an Arkray Super-Glucocard™ II glucometer (Arkray, 
Minnesota, USA) (2011–2012) or a Roche Accu-Chek 
Inform II (F. Hoffmann-La Roche Ltd, Basel, Switzerland) 
(2012–2015).
SPRINT, the predecessor to STAR, used the same entry 
criteria as STAR and used the same insulin delivery pro-
cedures [8, 10]. Blood for BG measurement was also 
typically taken directly from an arterial line and meas-
ured using an Arkray Super-Glucocard™ II glucometer 
(Arkray, Minnesota, USA). Both SPRINT and STAR rely 
on closely related models of the glucose–insulin system 
[30, 36]. SPRINT was a paper-based protocol that was 
developed using the model to optimize recommended 
insulin and nutrition delivery based on measured BG 
and previous interventions [8]. However, in use, SPRINT 
could not explicitly calculate insulin sensitivity, or for-
ward-predict the outcomes of interventions. In contrast, 
Table 1 Episode filtering statistics
Number of episodes (%) SPRINT Christchurch STAR Christchurch STAR Gyula
Initial number 487 625 68
Different GC target to protocol 0 (0.0 %) 225 (36.0 %) 11 (16.2 %)
Episode length <10 h 58 (11.9 %) 49 (7.8 %) 6 (8.8 %)
Fed over 120 % target 74 (15.2 %) 15 (2.4 %) 4 (5.9 %)
Remaining for analysis 355 (72.9 %) 336 (53.8 %) 47 (69.1 %)
Table 2 Patient demographics for  the STAR and  SPRINT 
Christchurch cohorts








Total patients 292 267
Age 63 [48:73] 65 [55:72] 0.28
Percent male 62.7 65.5 0.48
Length of ICU stay 6.2 [2.7:13.0] 5.7 [2.5:13.4] 0.70
% Operative 38.7 34.8 0.38
APACHE II score 19.0 [15.0:24.5] 21.0 [16.0:25] <0.05
APACHE II RoD (%) 29.0 [16.0:51.0] 33.0 [15.0:53.0] 0.41
ICU mortality (%) 18.2 24.3 0.08
Hospital mortality (%) 26.0 30.0 0.35
Hospital SMR 0.76 0.86 –
Mortality on GC  
protocol (%)
5.5 6.4 0.72
Table 3 Patient demographics for  the STAR Christchurch 
and Gyula cohorts
Data are presented as median [inter-quartile range (IQR)] where appropriate
Cohort characteristics STAR Gyula STAR Christchurch P value
Total patients 47 267
Age 66 [58:71] 65 [55:72] 0.72
Percent male 61.7 65.5 0.62
Length of ICU stay 14 [8.0:20.5] 5.7 [2.5:13.4] <0.05
APACHE II score 32.0 [28.0:36.0] 21.0 [16.0:25] <0.05
ICU Mortality (%) 38.3 24.3 0.05
Mortality on GC protocol 
(%)
0 6.4 0.09
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STAR implements the glucose–insulin model on tab-
let computer and therefore identifies insulin sensitivity, 
allowing forward prediction of interventions to optimize 
treatments, directly manage the risk of hypoglycemia and 
personalize care [28].
For both protocols in Christchurch Hospital ICU, 
patients received a similar feed type. SPRINT patients 
are typically fed enterally with either Glucerna™ 1 Cal. 
(34.3  % carbohydrate, 16.7  % protein, 14.4  g/L fiber, 
Abbott Labs, Illinois, USA) or Diabetic Resource (36  % 
carbohydrate, 24  % protein, 12  g/L fiber, Nestle Health 
Science, Epalinges, Switzerland). Similarly, STAR patients 
are typically fed Glucerna™ Select (31  % carbohydrate, 
20 % protein, 21.1 g/L fiber, Abbott Labs, Illinois, USA). 
Note all carbohydrate concentrations exclude indigest-
ible fiber. All the formulas used are within 1–4  % of 
total carbohydrate and protein content and thus provide 
very similar nutrition content for the patients over all 
of the years. For both protocols, parenteral nutrition is 
used occasionally to supplement enteral nutrition when 
necessary.
For both protocols, the same ACCP guidelines are 
used to determine the patients daily calorific goal intake 
of 25  kcal/kg/day [35] and enteral nutrition is advised 
between 30 and 100  % of this calorific goal [8, 28], 
although fixed nutrition rates and rates up to 120  % of 
calorific goal were included in this study. The main dif-
ference between the SPRINT and STAR feeding regime 
was SPRINT modulated feeding in steps up to ±10 % and 
effectively targeted 60–70 % of calorific goal [8], whereas 
STAR modulated feeding in steps up to ±30 % and tar-
geted 100 % of calorific goal [28].
Clinical practice and implementation: Gyula Hospital ICU, 
Hungary
Kálmán Pándy County Hospital (Gyula, Hungary), which 
is also a mixed ICU, has been using STAR in the medical 
ICU since December 2011. This ICU is markedly differ-
ent from Christchurch in terms of clinical GC practices. 
IV insulin is delivered via continuous infusion, and local 
nutrition guidelines specify aggressive early parenteral 
nutrition to supplement enteral nutrition to a similar goal 
feed rate of 25 kcal/kg/day. Patients are transitioned from 
parenteral to enteral nutrition as their stay progresses, 
and STAR modulates both rates to obtain total delivery 
values between 30 and 100 % of the daily goal.
Starting criteria for STAR in Gyula are also two suc-
cessive BG measurements over 8  mmol/L within a 4-h 
period, but are subject to the clinician’s choice, depend-
ing on expected length of stay and severity of illness of 
the patient. This difference in patient selection is given 
in Table  3, with the Gyula cohort having much higher 
Apache II scores and ICU length of stay. BG is measured 
using the E77 Elektronika Dcont Optimum or Dcont 
Personal Glucometers (E77, Budapest, Hungary) with 
blood taken directly from an arterial line. It should be 
noted that only one STAR tablet is available for use in the 
Kálmán Pándy County Hospital, thus limiting the patient 
numbers and increasing the severity of illness of these 
patients, as it was typically used for the most ill patients.
Patients and episodes of GC
As a single patient may be treated by a protocol on sev-
eral distinct occasions separated by significant breaks, a 
distinction is made between a patient and an episode of 
GC. A patient is considered to be a person with the same 
ICU admission number, and an episode is considered to 
be a period of contiguous treatment by GC. Therefore, 
there can be multiple episodes per patient.
An episode was defined as a period of GC (10  h or 
more) in which there are no breaks in BG measurements 
longer than 5 h. If a gap in data exceeded 5 h, it was con-
sidered that GC had been stopped and restarted. Con-
sidering the maximum measurement interval is 3 h, this 
choice accounts for reasonable variance in measurement 
intervals.
Analysis and statistics
The mortality on GC was calculated by working out the 
number of patients that died while on the GC protocol 
or within 5  h of the GC protocol ending. This statis-
tic is used to identify patients for whom GC might have 
impacted their ICU mortality.
Blood glucose performance statistics are presented in 
median and inter-quartile range of individual patients 
mean and standard deviations of blood glucose as per 
Finfer et al. [36]. All hypoglycemia and other rare occur-
rences were manually verified. Due to irregular sampling 
intervals, patient episode BG data were also analyzed 
after linear interpolation at 60-min intervals. The BG val-
ues at 60-min intervals (either clinical or interpolated) 
are presented in median and inter-quartile range of indi-
vidual episodes mean and standard deviations of BG, as 
above.
The mean hourly nutrition rates of glucose reported in 
Table  5 are nutrition rates excluding the hours patients 
were not fed, as occasionally patients could not be fed 
due to clinical reasons irrespective of the GC proto-
col. The standardized mortality ratio (SMR) calculated 
in Table  2 was calculated using the APACHE II Risk of 
Death.
Nonparametric statistics are used exclusively for all 
the comparative tests due to the typically skewed dis-
tributions of BG, insulin dose and other data. P values 
were computed using the Mann–Whitney rank-sum 
test for all continuous data and the Chi-squared test for 
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The cohort demographics in Table  2 show the SPRINT 
and STAR Christchurch cohorts have no significant dif-
ference in gender, age, operative status or ICU length of 
stay. However, the STAR cohort had higher APACHE II 
scores and ICU mortality rates than the SPRINT cohort.
Table  5 presents the per-patient and per-episode 
GC safety and performance of STAR and SPRINT in 
Christchurch. These results show that both STAR and 
SPRINT protocols resulted in over 86 % time in the BG 
band of 4.4–8.0  mmol/L per episode (86.6 and 93.0  %, 
respectively), while maintaining safe control of severe 
hypoglycemia (BG < 2.2 mmol/L, 1.5 vs. 0.3 % of patients, 
respectively). SPRINT’s lower and tighter BG target 
range (4.4–6.1  mmol/L), resulted in an increased inci-
dence of moderate hypoglycemia (BG < 4.0 mmol/L, 62.0 
vs. 26.3  % of patients for SPRINT and STAR, respec-
tively) compared with STAR.
Table  4 presents the cohort results of GC safety and 
performance of STAR and SPRINT in Christchurch. In 
targeting this 4.4–8.0  mmol/L range using model-pre-
dictive methods to personalize treatment, STAR reduced 
clinical workload in the same ICU (13.6 measurements 
per day per patient compared to 15.8, P < 0.05, Table 4) 
and increased nutrition delivery per episode compared 
with SPRINT (achieving 86  % of ACCP calorific goal 
feed compared to 73 %, P < 0.05, Table 5), when allowed 
to feed. It did so while maintaining consistent GC for a 
more critically ill and thus potentially more metabolically 
variable cohort [13].
STAR Christchurch versus STAR Gyula
The cohort demographics in Table  3 show the STAR 
Christchurch and Gyula cohorts have no significant dif-
ference in gender or age. However, the STAR Gyula had 
much higher APACHE II scores (32 vs. 21, P < 0.05), ICU 
length of stay (14 vs. 5.7  days, P  <  0.05) and ICU mor-
tality rates (38.3  % vs. 24.3, P  =  0.05) than the STAR 
Christchurch cohort.
Despite a significant increase in the severity of illness, 
STAR demonstrated consistent effective GC perfor-
mance over the Gyula cohort. Table  5 shows that both 
Christchurch and Gyula STAR cohorts achieved over 
86  % of time in its target range (4.4–8.0  mmol/l) per 
episode (86.6 and 87.1  %, respectively, P =  0.81), while 
maintaining very safe control of hypoglycemia per epi-
sode, <4.0  mmol/L (0.0 and 0.9  % of time, respectively, 
P < 0.05).
Table 4 Cohort glycemic control results for the STAR and SPRINT cohorts in Christchurch and Gyula Hospital ICU
Data are presented as median [inter-quartile range (IQR)] where appropriate
SPRINT Chch STAR Chch STAR Gyula P value
SPRINT Chch, STAR Chch STAR Gyula, STAR Chch
Number patients 292 267 47 – –
Number episodes 355 336 47 – –
Total hours 40931 22948 6244 – –
Number of BG measurements 26530 12363 3050 – –
Median (IQR) days on protocol 3.0 [1.3:6.3] 1.9 [0.9:3.5] 3.9 [1.9:6.9] <0.05 <0.05
Median (IQR) measures/day per patient 15.8 [14.1:18.0] 13.6 [11.5:16.2] 11.7 [10.9–13.3] <0.05 <0.05
Glycemic performance—cohort raw data
BG mean 5.8 7.0 6.8 – –
BG SD 1.3 1.3 1.3 – –
BG median [IQR] 5.7 [5.0–6.6] 6.8 [6.0–7.9] 6.7 [5.8–7.8] <0.05 <0.05
Glycemic performance—cohort hourly interpolated
BG mean 5.7 6.7 6.6 – –
BG SD 1.2 1.2 1.2 – –
BG median [IQR] 5.6 [5.0–6.4] 6.6 [6.0–7.4] 6.5 [5.9–7.2] <0.05 <0.05
% time >10.0 mmol/l 1.5 4.4 3.0 – –
% time 4–6.1 mmol/l (SPRINT target) 71.4 43.9 46.5 – –
% time 4.4–8.0 mmol/l (STAR target) 87.2 82.6 85.7 – –
% time <4.4 mmol/l 7.4 1.4 1.9 – –
% time <4.0 mmol/l 2.5 0.6 0.9 – –
% time <2.22 mmol/l 0.002 0.004 0 – –
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Figure  1 shows the STAR BG distributions in these 
two ICUs are almost identical although P < 0.05 due to 
very large number of measurements. The per-patient BG 
mean and standard deviation were also very similar for 
both of the cohorts (P = 0.6 and 0.5, respectively). Thus, 
this evidence suggests that STAR is able to deliver con-
sistent GC to different cohorts with significantly different 
clinical practices and illness severity.
Table  4 presents the cohort results of GC safety and 
performance of STAR in Christchurch and Gyula. Com-
pared with the Christchurch, the Gyula clinical staff 
chose to use longer intervention intervals (11.7 vs. 13.6 
measurements per day, P < 0.05) and feed a significantly 
higher amount of glucose per episode (5.1 vs. 7.4  g/h, 
P < 0.05, Table 5), largely due to their higher carbohydrate 
parenteral feed regime, thus demanding higher insulin 
dosing per episode (2.7 vs. 3.2 U/h, P  <  0.05, Table  5) 
and amplifying the effects of insulin sensitivity variations 
[24]. This ultimately resulted in the Gyula cohort having 
a higher occurrence of moderate hypoglycemia (26.3 vs. 
53.2 % of patients BG < 4.0 mmol/L, P < 0.05).
Discussion
Cohort Demographics
Table 2 shows that there has been a shift in severity of ill-
ness in the Christchurch ICU over the past 7 years, with 
the patients on STAR being more critically ill on average 
than those on SPRINT. This phenomenon is not wholly 
unexpected. Increasing economic and demographic 
stress worldwide has placed greater demand on limited 
bed spaces. In highly occupied units like Christchurch 
(2.2 beds/1000 people), admission may be limited to the 
more critically ill [37].
The apparent increase in ICU mortality of patients on 
STAR compared with SPRINT could be due to the ICU 
experiencing a reduction in pressure to transfer patients 
not expected to survive to the ward. The hospital SMR 
reported in Table 2 shows an increase between the SPRINT 
Table 5 Per-patient and per-episode glycemic control results for the STAR and SPRINT cohorts in Christchurch and Gyula 
Hospital ICU
Data are presented as median [inter-quartile range (IQR)] where appropriate
SPRINT Chch STAR Chch STAR Gyula P value
SPRINT Chch, STAR Chch STAR Gyula, STAR Chch
Number patients 292 267 47 – –
Number episodes 355 336 47 – –
Glycemic performance—per-patient raw data
Median [IQR] BG mean 5.9 [5.5–6.3] 7.0 [6.6–7.6] 6.9 [6.6–7.4] <0.05 0.60
Median [IQR] BG SD 1.2 [1.0–1.6] 1.5 [1.2–2.1] 1.6 [1.3–1.9] <0.05 0.50
Median [IQR] BG median 5.7 [5.3–6.1] 6.7 [6.3–7.3] 6.6 [6.3–7.1] <0.05 0.28
# (%) Patients <4.0 mmol/l 181 (62.0 %) 70 (26.3 %) 25 (53.2 %) <0.05 <0.05
# (%) Patients <2.22 mmol/l 1 (0.3 %) 4 (1.5 %) 2 (4.3 %) 0.20 0.22
Glycemic performance—per-episode hourly interpolated
Median [IQR] BG mean 5.8 [5.4–6.2] 6.7 [6.4–7.3] 6.7 [6.5–7.1] <0.05 0.60
Median [IQR] BG SD 1.1 [0.8–1.5] 1.2 [0.9–1.7] 1.3 [1.04–1.5] <0.05 0.23
Median [IQR] BG median 5.6 [5.2–6.0] 6.5 [6.2–7.0] 6.5 [6.3–6.7] <0.05 0.61
% time >10.0 mmol/l 0.0 [0.0–1.6] 1.6 [0.0–6.5] 2.4 [0.7–5.4] <0.05 0.16
% time 4–6.1 mmol/l (SPRINT target) 65.6 [52.4–77.9] 29.8 [12.4–45.9] 33.3 [21.5–40.9] <0.05 0.49
% time 4.4–8.0 mmol/l (STAR target) 93.0 [85.0––97.5] 86.6 [75.0–94.1] 87.1 [79.3–91.1] <0.05 0.81
% time <4.4 mmol/l 7.3 [2.1–16.1] 0.0 [0.0–1.8] 0.9 [0.0–2.8] <0.05 <0.05
% time <4.0 mmol/l 1.4 [0.0–5.71] 0.0 [0.0–0.0] 0.0 [0.0–1.8] <0.05 <0.05
% time <2.22 mmol/l 0.0 [0.0–0.0] 0.0 [0.0–0.0] 0.0 [0.0–0.0] 0.97 0.71
Intervention performance—per episode (excluding not fed)
Median [IQR] mean insulin (U/h) 2.2 [0.0–2.8] 2.7 [1.9–3.5] 3.2 [2.4–4.6] <0.05 <0.05
Total hours not fed (%) 16430 (40.1 %) 2305 (10.0 %) 0 (0.0 %) – –
Median [IQR] mean goal feed (%) 73 [52–86] 86 [64–97] 80 [74–88] <0.05 0.28
Median[IQR] mean total glucose(g/h) 4.2 [3.1–5.4] 5.1 [4.0–6.2] 7.4 [6.2–8.9] <0.05 <0.05
Median [IQR] mean enteral glucose (g/h) 4.1 [3.0–5.3] 4.5 [2.6–5.6] 3.04 [1.48–5.40] 0.74 <0.05
Median [IQR] mean parenteral glucose  
(g/h)
0.0 [0.0–0.0] 0.0 [0.0–1.1] 4.05 [2.84–5.69] <0.05 <0.05
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and STAR Christchurch cohorts (0.76 vs. 0.86, respectively). 
This suggests that the APACHE II risk of death scores is 
slightly more representative of the cohort’s illness in the 
STAR cohort compared with the SPRINT cohort. The sig-
nificant difference in the severity of illness between the 
STAR Gyula cohort and the Christchurch cohorts is largely 
due to the different entrance criteria, as only one STAR tab-
let computer is available and STAR is thus reserved for the 
more critically ill patients, as clinically selected.
STAR versus SPRINT
Compared with SPRINT, both STAR cohorts had slightly 
lower time in the 4.4–8.0 mmol/L band per episode (86.6 
and 87.1  % vs. 93.0  %). SPRINT targeted a lower and 
tighter range (4.4–6.1 mmol/L), resulting in an increased 
incidence of moderate hypoglycemia (BG < 4.0 mmol/L, 
62.0 vs. 26.3  % and 53.2  % of patients) compared with 
STAR. However, recent studies have shown that time in 
the essentially same band, 3.9–7.8 mmol/L, is associated 
with improved outcomes [34], supporting this slightly 
higher upper target limit of 8.0 mmol/L.
Flexibility to patient-specific requirements is a critical 
aspect of the STAR model-based protocol as the tablet 
application allows nursing staff to enter any information 
that may change the patient’s insulin or nutrition require-
ments. This approach allows STAR to adapt to patient-
specific needs and provide appropriate recommendations 
that take into account all necessary considerations. Con-
versely, STAR achieved 96.8 % compliance from nursing 
staff (unchanged interventions) for nutrition delivery and 
99.5 % for insulin interventions.
SPRINT was deliberately designed to target nutrition 
to 60–70  % or lower for control, which reduced insulin 
requirements and thus risk of hypoglycemia [31, 38]. 
SPRINT had a maximum 2-h measurement rate for the 
same reasons of risk mitigation which increased work-
load relative to STAR’s 3-h maximum. In addition, the 
tighter SPRINT target (4.4–6.1  mmol/L) is also part of 
the reason for this increased nurse workload and lower 
feeding on SPRINT. For STAR, the use of stochastic risk 
models and virtual patient design in silico enabled the 
lower workload and play a role in the higher nutrition 
possible, although a wider overlapping target band also 
enables some of this increased nutrition
Both STAR and SPRINT Christchurch have the same 
starting and stopping criteria. However, patients on 
STAR Christchurch required insulin therapy for 36.7  % 
fewer days than SPRINT (P < 0.05, Table 4). Differences 
that could account for this significant reduction in length 
of treatment for a more critically ill cohort include:
1. Significantly reduced incidence of moderate hypogly-
cemia (BG < 4.0 mmol/L) with STAR.
2. Slightly higher median BG with STAR, with similar 
BG in the 4.4–8.0 mmol/L range.
3. Increased mortality on the STAR protocol.
4. Increased amount of carbohydrate, protein, fiber and 
nutrition content delivered by STAR.
The number of patients experiencing moderate hypo-
glycemia is not enough to account for the size of this 
change. A recent analysis by Krinsley et  al. [34] sug-
gests that the 3.9–7.8 mmol/L band, similar to that tar-
geted by STAR, is beneficial. Despite the lower median 
BG for SPRINT, the time in the 4.4–8.0 mmol/L band is 
very similar for both protocols. ICU and hospital mor-
tality were higher for STAR due to changes in the illness 
severity and demographic factors, as given in Table  2. 
However, the percentage mortality while on the respec-
tive GC protocol is very similar (5.5 vs. 6.4 %, P = 0.72, 
Table 2), suggesting that the reduction in period of GC 
is less likely to be attributed to the cohorts respective 
mortality. This outcome leaves the increased carbohy-
drate, protein, fiber and overall nutrition intake as a 
potential reason for the reduced length of GC. How-
ever, there is significant debate about the role of energy 
and protein delivery in critical illness [39], with some 
literature showing increased calorific intake levels 
that are still below the 100  % calorific goal have ben-
eficial effects [40] and others showing no effect [41]. In 
this study, the median per-episode feed for the STAR 
Christchurch cohort was 86  % of calorific goal feed, 
shown by Heyland et al. [42] to be a region of reduced 
risk of death.
BG [mmol/L]


























Fig. 1 BG CDF—resampled hourly. Cumulative density plots compar-
ing the STAR Christchurch, STAR Gyula, SPRINT Christchurch cohorts 
hourly resampled BG. The target band 4.4–8.0 mmol/L is shown in the 
green bar
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STAR Christchurch versus STAR Gyula
STAR entry criteria were the same in both units based 
on hyperglycemia (BG > 8.0 mmol/L) or clinician choice. 
STAR was used for a patient through their entire stay or 
multiple episodes of stay in Gyula and is the standard 
of care for the Christchurch ICU for all GC. Hence, the 
study, while a retrospective analysis, is run essentially 
prospectively in that all patients who had STAR with the 
same target band were included from each unit.
One difference between Gyula and Christchurch 
cohorts is that with a single tablet to run STAR in Gyula, 
clinician’s likely chose the more ill patients they thought 
would benefit. This choice could likely have biased the 
severity of illness upwards, as well as the length of stay 
(Table 3). It may have similarly affected the difference in 
ICU mortality in Table 3, although this comparison is sig-
nificantly underpowered given the low patient numbers 
in Gyula and could thus also be due to statistical varia-
tion. Hence, variation in these cohorts is biased by this 
choice, and the results in Table  3 could be due to one 
or a combination of these factors, making GC in this 
cohort easier or more difficult depending on the patients 
selected. However, this difference is not as relevant to 
showing that STAR can provide safe, effective GC results 
across very different patients and clinical practices.
In the STAR Christchurch cohort, four patients expe-
rienced severe hypoglycemia, and in the Gyula cohort, 
two patients experienced severe hypoglycemia. STAR’s 
model-based predictive GC forward predicts potential 
patient-specific behavior using the 5th and 95th percen-
tile, choosing an intervention to optimize the placement 
of these stochastic bounds [28, 33]. Therefore, all of the 
hypoglycemic cases occurred outside of STAR’s cohort-
based model-predictive bounds. Each of these patients 
had a 99th percentile (outlier) patient-specific model-
based insulin sensitivity during their hypoglycemic epi-
sode, and the number of events suggests this is a 1-in-100 
event, which broadly matches the cohort results given in 
Table 5.
Limitations
A total of 19 patients were excluded from the STAR 
Christchurch (15) and Gyula (4) analysis as they received 
more than 120 % of ACCP recommended caloric target 
on average. In some instances, the high level of nutrition 
may be clinically specified, but in most cases the high 
level of nutrition is due to nursing staff choosing to fix 
enteral and/or parenteral feed on STAR.
The discrepancy in patient numbers between the two 
STAR cohorts, over approximately the same time period, 
is due to only one of STAR tablet being available in 
Gyula, compared with 10 in Christchurch. The number of 
patients in the Gyula cohort is low, and therefore, we do 
not have enough power (52 %, p test) for comparison to 
the Christchurch cohort in relation to raw mortality on 
the STAR GC protocol in Gyula, or morbidity and per-
patient BG statistics (e.g., per-patient TIB, mean/median 
BG). Sufficiently more patients would be required for a 
well powered outcome study on mortality or morbidity.
It should be noted that there was patient selection 
bias for STAR Gyula, creating significantly different 
cohorts in terms of ICU length of stay and severity of 
illness (P  <  0.05, Table  3). The difference in the cohorts 
could result in GC being more complex or simpler in the 
Gyula cohort relative to the Christchurch cohort due to 
more severely ill patients being more variable or possibly 
longer length of stay patients being more stable.
It is worth noting that both severe hypoglycemic events 
on STAR, in Christchurch, occurred at high fixed nutri-
tion rates over 100  % of ACCP goal feed, but <120  %. 
High fixed nutrition rates raise a patients BG all else 
equal, resulting in the need for higher or maximum insu-
lin rates to control hyperglycemia. The large amount of 
insulin in the patient then amplifies any small changes in 
the patient’s insulin sensitivity due to changes in condi-
tion, significantly reducing the ability to control BG safely 
and effectively [24]. Despite high fixed nutrition inputs, 
up to 120  % goal feed in some cases, making glycemic 
control more difficult, it is also an important feature of 
the STAR application, allowing it to be more flexible to 
specific clinical needs. However, in these specific cases 
lower (100  % or less) and/or variable nutrition would 
have allowed greater safety [28].
As mentioned previously, STAR and SPRINT target dif-
ferent BG bands (4.4–8.0  mmol/L and 4.4–6.1  mmol/L, 
respectively). These BG targets overlap but vary in width 
and level of BG, and therefore, the comparison of these 
two protocols in terms of percentage of time in 4.4-
8.0 mmol/L BG band may be an unfair statistic consider-
ing that only one the protocols actually targeted this band. 
The only way to fairly compare the two protocols perfor-
mance would be if they both targeted the same BG target.
To compare the STAR GC protocol to other ICU GC 
protocols is difficult as the cohorts need to be similar, 
and the same statistics need to be reported. Considering 
performance, safety and workload to achieve them, other 
studies have shown similar performance based on time 
in band [43–46]. STAR achieved these performance and 
safety results with a lower relative clinical workload over 
a much larger, more diverse and relatively very ill cohort. 
With the data available, it appears that STAR performs 
very well in comparison with other current ICU GC pro-
tocols with better safety and lower workload. However, 
a best protocol cannot be determined without the same 
statistics being reported and the cohorts being much 
more similar.
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Sensor error can affect the quality of control [47], 
particularly in target to value protocols [48]. SPRINT 
was designed in silico to be robust to these errors for 
the Arkray Super-Glucocard™ II glucometers used 
(CV  <  10  % [49]). STAR is more robust to this error as 
its integral-based identification of insulin sensitivity in 
the model filters the error [50], and its target to range 
approach and the outlying changes in insulin sensitivity 
in the stochastic model used to guide control are more 
robust to these errors. In addition, Christchurch Hospital 
ICU changed to the more reliable Accu-Chek Infor II glu-
cometer in 2012 (CV ≤ 3.2 % [51]). The Gyula unit used a 
E77 Elektronika Dcont Optimum or Dcont Personal Glu-
cometers (CV < 4.6 %).
By using model-based predictive GC tailored to 
patient-specific metabolic response, through identifying 
their respective time variant insulin sensitivity, safe and 
effective GC can be offered. With the stochastic models 
of insulin sensitivity variability used, STAR thus directly 
manages inter- and intra-patient variability to improve 
safety. Other protocols could have failed in the past due 
to their inability to adjust for this inter- and intra-patient 
variability via model-based GC on a computer. Consider-
ing that this study is a retrospective analysis, as opposed 
to a randomized control trial, we cannot explicitly link 
the outcomes to GC. Thus, the main focus of this study is 
to demonstrate that safe, effective and generalizable GC 
is possible.
Conclusions
This retrospective, observational study analyzed the GC 
safety, performance and generalizability of the STAR 
protocol in Christchurch, New Zealand and Gyula, Hun-
gary. Results of STARs predecessor, SPRINT, were pre-
sented for comparison. Patients on the STAR protocol 
spend over 86 % of all time on protocol within the goal 
4.4-8.0  mmol/L BG band, with very few occurrences of 
severe or moderate hypoglycemia. STAR outperformed 
SPRINT by providing higher nutrition and safe, effective 
control for all days of stay, as well as reducing time on 
protocol and workload.
Overall, in Christchurch, the STAR framework has 
shown an ability to adapt well to a wide range of situa-
tions, and provide safe and effective treatment at all 
times. It has also reduced clinical burden in the ICU, by 
lowering the number of measurements and interventions 
needed to achieve equivalent control to SPRINT, while 
improving safety.
A key criterion for success in any protocol is the ability 
to demonstrate high performance and high safety across 
patient types, time, clinical practice culture and clinical 
resources. The results of the STAR protocol in Gyula, 
Hungary, are used to analyze this criterion. The results 
show that STAR has comprehensively met these crite-
ria, with the BG distributions of the two cohorts being 
almost identical even though the clinical practices are 
significantly different.
Thus, this research shows how a model-based and per-
sonalized approach to GC can safely improve care and 
reduce workload across differing clinical practices.
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